Patient Leaflet Updated 05-May-2023 | Celix Pharma Ltd
Vecit 6 mg/0.4 mg Modified-release Tablets
Vecit 6 mg/0.4 mg Modified-release Tablets
solifenacin succinate/tamsulosin hydrochloride
1. What Vecit is and what it is used for
2. What you need to know before you use Vecit
3. How to use Vecit
4. Possible side effects
5. How to store Vecit
6. Contents of the pack and other information
Vecit is a combination of two different medicines called solifenacin and tamsulosin in one tablet. Solifenacin belongs to a group of medicines called anticholinergics and tamsulosin belongs to a group of medicines called alpha-blockers.
This medicine is used in men to treat moderate to severe storage and voiding symptoms of the lower urinary tract, which are caused by bladder problems and an enlarged prostate (benign prostatic hyperplasia).
Vecit is used when previous treatment with a single product for this condition did not relieve symptoms adequately.
As the prostate grows, it can lead to problems empyting your bladder (voiding symptoms) such as hesitancy (difficulty starting to urinate), difficulty urinating (poor stream), dribbling and a feeling of incomplete bladder emptying. At the same time, the bladder is also affected and contracts spontaneously at times when you do not want to void. This causes storage symptoms such as changes in bladder sensation, urgency (having a strong, sudden desire to urinate without prior warning), and having to urinate more frequently.
Solifenacin reduces the undesired contractions of your bladder and increases the amount of urine that your bladder can hold. Therefore, you can wait longer before you have to go to the toilet. Tamsulosin enables urine to pass more readily through the urethra (the tube that carries urine from the bladder to the outside of the body) and helps urination.
Tell your doctor if you think that any of these conditions apply to you.
Talk to your doctor or pharmacist before using this medicine if:
Do not give this medicine to children and adolescents.
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
It is especially important to inform your doctor if you are using:
This medicine can be taken with or without food, as you prefer.
Vecit is not for use by women.
In men, abnormal ejaculation has been reported. This means that the semen does not leave the body via the urethra (the tube that carries urine from the bladder to the outside of the body), but instead goes into the bladder or the ejaculation volume is reduced or absent. This is harmless.
Vecit might cause dizziness, blurred vision, tiredness and, uncommonly, sleepiness. If you suffer from these side effects, do not drive or operate machinery.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The maximum daily dose is one tablet (containing 6 mg of solifenacin and 0.4 mg of tamsulosin). Swallow with water by mouth with or without food, as you prefer. Do not crush or chew the tablet.
If you have taken more tablets than you have been told to take, or if someone else accidentally takes your tablets, contact your doctor, pharmacist or hospital immediately for advice.
Do not try to make yourself sick.
Symptoms of overdose may include: dry mouth, dizziness, and blurred vision, perceiving things that are not there (hallucinations), over-excitability, seizures, difficulty breathing, increased heart rate, inability to completely or partially empty the bladder or pass urine (urinary retention) and/or an unwanted decrease in blood pressure.
Take your next tablet as normal. Do not take a double dose to make up for a forgotten tablet.
If you stop taking this medicine, your original complaints may return or worsen. If you are considering stopping the treatment, always consult your doctor,
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Vecit can cause side effects, although not everybody gets them.
Stop taking Vecit and tell your doctor immediately if you experience:
The most serious side effect is a sudden inability to pass urine (acute urinary retention). This is an uncommon side effect observed during treatment with solifenacin/tamsulosin in clinical studies (may affect up to 1 in 100 men).
If you think you may have this, see a doctor straight away. You may need to stop treatment with this medicine.
Talk to your doctor or pharmacist if you get any of the following side effects or any possible side effects not listed in this leaflet.
Common side effects (may affect up to 1 in 10 men)
Other uncommon side effects (may affect up to 1 in 100 men)
Rare side effects (may affect up to 1 in 1,000 men)
Very rare side effects (may affect up to 1 in 10,000 men)
Frequency not known (frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or blister after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Vecit Modified-release Tablets are round, biconvex, red, film-coated tablets, debossed with “6 04” on one side.
Vecit Modified-release Tablets are available in PA/Aluminium/ PVC/Aluminium blister packs containing 10, 20, 30, 50, 60, 90, 100 or 200 tablets.
Not all pack sizes may be marketed.
If you are blind or partially sighted and require this leaflet in a different format, call 0800 669 6825 or contact [email protected].
This leaflet was last revised in September 2022.
CEL00047
12 Constance Street, International House, London, E16 2DQ, UK
0800 669 6825
http://www.celixpharma.com/
0800 669 6825
+44 (0)203 105 6525